iobiotech.com (IOBT): Rasio rega marang prakiraan pendapatan
The forward P/S dynamics on the GURU.Markets chart reflect revenue expectations from the sale of IO102-IO103 cancer vaccines. Innovative developments by IO Biotech, Inc. (IOBT) break down tumor defense barriers, enhancing overall therapy. However, the lack of profitable products leaves the company dependent on external financing, and the mark indicates the current state of this investment balance.
Rincian analitis perusahaan IO Biotech Inc. (IOBT)
- rega saham lan target rega konsensus:
- data kapitalisasi bursa:
- indikator nilai buku ekuitas:
- indikator total utang lan likuiditas perusahaan:
Rasio Total Utang marang Ekuitas IO Biotech, Inc.|IOBT - Rasio silihan jangka dawa marang modal|Utang jangka cendhak marang modal IO Biotech, Inc.|IOBT - Kewajiban utang agregat|Utang-utang marang kapitalisasi buku IO Biotech Inc.|IOBT - Utang jangka dawa|Utang jangka cendhak perusahaan IO Biotech|Rasio cepet iobiotech.com
- data bathi bisnis lan rasio investasi:
IOBT - Bathi resik|Bathi sing dikarepake IO Biotech, Inc.|IOBT - Kapitalisasi marang bathi resik|Prakiraan rega marang bathi IO Biotech Corp|IOBT - Rega marang bathi kanthi panyesuaian wutah|Pangali EV/EBITDA IO Biotech Inc.|IOBT - Pendapatan operasional sadurunge ngurangi amortisasi|Bathi saben saham sajrone rolas wulan pungkasan IO Biotech|IOBT - Bathi resik saben siji saham sajrone rolas wulan pungkasan|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan iobiotech.com|IOBT - Tambahing bathi saben saham ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep IO Biotech, Inc.
- rincian pendapatan lan dodolan:
Ringkesan analisis perusahaan:IO Biotech IOBT
IO Biotech, Inc. (IOBT) maintains a strong position in the development of anti-tumor vaccines, leveraging the trust of U.S. and Danish scientists. The expected revenue multiple compares the current market value of the business with projected income, allowing investors to quickly assess the fair value of the asset relative to the prospects of metastasis therapy without waiting for quarterly reports, as this chart reflects.
Analisis pesaing
ImmunityBio - Multiplikator forward rega marang pendapatan|Multiplikator Forward P/S Immunocore Holdings IMCR|JANX - Rasio rega marang prakiraan pendapatan|RCUS (Arcus Corp) - Kapitalisasi marang prakiraan pendapatan|Zymeworks Inc. (ZYME) - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep tangotx.com (TNGX)|Multiplikator forward rega marang pendapatan IOVA|IMTX - Prakiraan rega marang pendapatan|Multiplikator forward rega marang pendapatan XNCR (Xencor Corp)|Rasio rega marang pendapatan sing dikarepake CMPX|Multiplikator Forward P/S REPL (Replimune Group, Inc.)|Rega forward marang dodolan LYEL|Innate Pharma - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Pyxis Oncology, Inc.|cgen.com (CGEN) - Rasio rega marang prakiraan pendapatan|Sutro Biopharma, Inc - Rega forward marang dodolan|INKT (MiNK Therapeutics, Inc.) - Multiplikator Forward P/S|Multiplikator Forward P/S Werewolf|Rasio rega marang prakiraan pendapatan Immix Biopharma, Inc. (IMMX)|ALXO: Rega mangsa ngarep marang pendapatan|Cue Biopharma, Inc. - Multiplikator forward rega marang pendapatan|PDS Biotech (PDSB) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Sonnet BioTherapeutics Holdings Inc. - Multiplikator Forward P/S|Rasio kapitalisasi marang dodolan sing dikarepake MAIABiotech.com MAIA|Liminatus Pharma LLC (LIMN) - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep LAVA Therapeutics (LVTX)|Multiplikator forward rega marang pendapatan NXTC|LPTX: Rega forward marang dodolan|Multiplikator Forward P/S INTS|Rasio rega marang prakiraan pendapatan SNSE (senseibio.com)|Multiplikator Forward P/S TOVX (Theriva Biologics)|Rasio kapitalisasi marang dodolan sing dikarepake Gritstone bio Inc. (GRTS)|KA - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep NexImmune Corporation|TSBX (turnstonebio.com) - Multiplikator forward rega marang pendapatan|VCNX: Rasio rega marang pendapatan sing dikarepake|HARP (Harpoon Therapeutics, Inc.) - Multiplikator Forward P/S
